神经激肽B受体拮抗剂治疗多囊卵巢综合征女性:一项随机安慰剂对照试验
这项双盲、双模拟、安慰剂对照的2期试验纳入67例18-45岁多囊卵巢综合征女性,评估AZD4901(NK3受体拮抗剂)20、40或80 mg/日共28天的疗效。第7天,80 mg/日组LH曲线下面积较安慰剂降低52.0%,总睾酮降低28.7%,LH脉冲频率减少3.55次/8小时。
要点
- AZD4901 80 mg/日使LH曲线下面积较安慰剂降低52.0%(95%CI 29.6-67.3%)。
- AZD4901 80 mg/日使总睾酮较安慰剂降低28.7%(95%CI 13.9-40.9%)。
- AZD4901 80 mg/日使LH脉冲频率较安慰剂减少3.55次/8小时(95%CI 2.0-5.1)。
核心结论
- NK3受体拮抗剂AZD4901特异性降低LH脉冲频率,并随后降低血清LH和睾酮浓度,从而提出NK3受体拮抗可作为治疗PCOS中枢神经内分泌病理生理的潜在方法。
研究设计与样本
- 双盲、双模拟、安慰剂对照的2期试验,纳入大学医院和私立临床研究中心。
- 共67例患者被随机分组,其中65例可评估。
- 受试者为18-45岁多囊卵巢综合征女性。
- 干预为AZD4901(特异性神经激肽-3受体拮抗剂)20、40或80 mg/日或匹配安慰剂,共28天。
主要发现
- 第7天,80 mg/日AZD4901组相对安慰剂的基线校正变化:LH曲线下面积降低52.0%(95%CI 29.6-67.3%)。
- 第7天,80 mg/日AZD4901组相对安慰剂的总睾酮浓度降低28.7%(95%CI 13.9-40.9%)。
- 第7天,80 mg/日AZD4901组相对安慰剂的LH脉冲频率减少3.55次/8小时(95%CI 2.0-5.1)。
- 上述结果均为名义P<.05。
关键数值与推荐
- 主要结局指标为第7天8小时LH血清浓度-时间曲线下面积相对安慰剂的基线变化。
临床怎么用
- 原文结论提出NK3受体拮抗可作为治疗PCOS中枢神经内分泌病理生理的潜在方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is characterized by high secretion levels of LH and T. Currently, there is no treatment licensed specifically for PCOS. OBJECTIVE: The objective of this study was to investigate whether a targeted therapy would decrease LH pulse frequency in women with PCOS, subsequently reducing serum LH and T concentrations and thereby presenting a novel therapeutic approach to the management of PCOS. DESIGN: This study is a double-blind, double-dummy, placebo-controlled, phase 2 trial. SETTINGS: University hospitals and private clinical research centers were included. PARTICIPANTS: Women with PCOS aged 18-45 years participated. INTERVENTION: Intervention included AZD4901 (a specific neurokinin-3 [NK3] receptor antagonist) at a dose of 20, 40, or 80 mg/day or matching placebo for 28 days. MAIN OUTCOME MEASURE: Change from baseline in the area under the LH serum concentration-time curve over 8 hours (area under the curve) on day 7 relative to placebo was measured. RESULTS: Of a total 67 randomized patients, 65 were evaluable. On day 7, the following baseline-adjusted changes relative to placebo were observed in patients receiving AZD4901 80 mg/day: 1) a reduction of 52.0% (95% confidence interval [CI], 29.6-67.3%) in LH area under the curve; 2) a reduction of 28.7% (95% CI, 13.9-40.9%) in total T concentration; and 3) a reduction of 3.55 LH pulses/8 hours (95% CI, 2.0-5.1) (all nominal P < .05). CONCLUSIONS: The NK3 receptor antagonist AZD4901 specifically reduced LH pulse frequency and subsequently serum LH and T concentrations, thus presenting NK3 receptor antagonism as a potential approach to treating the central neuroendocrine pathophysiology of PCOS.
引用
- George JT, Kakkar R, Marshall J, et al. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2016. PMID: 27459523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。